Advertisement

Mammakarzinom pp 132-152 | Cite as

Therapie des metastasierenden Mammakarzinoms

  • C. Zielinski
Part of the Angewandte Onkologie book series (AONKOLOGIE)

Zusammenfassung

Obwohl viele Patientinnen mit Mammakarzinom in den Stadien I oder II mit Hilfe moderner chirurgischer, strahlentherapeutischer und adjuvanter internistisch-onkologischer Methoden von ihrer Erkrankung prinzipiell geheilt werden können, entwickeln etwa 40% aller Patientinnen mit Mammakarzinom eine metastasierende Erkrankung. Angesichts der Tatsache, daß es sich beim Mammakarzinom um einen sehr häufigen Tumor handelt — derzeit tritt die Erkrankung bei etwa jeder zehnten Bürgerin der Vereinigten Staaten von Amerika auf —, ist das Problem der Behandlung des metastasierenden Mammakarzinoms von großer klinischer Relevanz. Trotz einer breiten Palette von zur Verfügung stehenden Chemo- und Hormontherapeutika ist es aber bis jetzt nicht möglich, das metastasierende Mammakarzinom zu heilen, sodaß davon ausgegangen werden muß, daß die Metastasierung bei allen Patientinnen früher oder später zum Tod führt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Henderson IC (1984) Chemotherapy for advanced disease. In: Bonadonna G (ed) Breast cancer: diagnosis and management. Wiley, Chichester New York Brisbane Toronto Singapore, p 247Google Scholar
  2. 2.
    Dunphy FR, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8: 1207PubMedGoogle Scholar
  3. 3.
    Greenspan EM (1965) Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 33: 1Google Scholar
  4. 4.
    Cooper R (1969) Combination cytotoxic chemotherapy in hormone resistant breast cancer. Proc AACR 10: 15Google Scholar
  5. 5.
    Broder LE, Tormey DC (1974) Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev 1: 183CrossRefGoogle Scholar
  6. 6.
    Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiamine platinum (cisDDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108PubMedCrossRefGoogle Scholar
  7. 7.
    Carbone PP, Davis TE (1978) Medical treatment for advanced breast cancer. Semin Oncol 4: 417Google Scholar
  8. 8.
    Carter SK (1974) The chemical therapy of breast cancer. Semin Oncol 1: 131PubMedGoogle Scholar
  9. 9.
    Davidson NE, Lippman ME (1988) Treatment of metastatic breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and management of breast cancer. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 375Google Scholar
  10. 10.
    Pötzi P, Zielinski C, Kühböck J (1985) Mitoxantrone in the treatment of advanced solid tumors. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, TokyoGoogle Scholar
  11. 11.
    Henderson IC, Allegra JC, Woodcock T, et al (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560PubMedGoogle Scholar
  12. 12.
    Chlebowski RT, Irwin LE, Pugh RP, et al (1979) Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39: 4503PubMedGoogle Scholar
  13. 13.
    Zielinski CC (1991) Zytostatische Chemotherapie. In: Grabner G, Geyer G (Hrsg) Innere Medizin. Maudrich, Wien (in Druck)Google Scholar
  14. 14.
    Canellos GP, Pocock SJ, Taylor SG III, et al (1976) Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882PubMedCrossRefGoogle Scholar
  15. 15.
    Mouridsen HT, Palshof T, Brahm M, et al (1977) Evaluation of single drug versus multiple drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61: 47PubMedGoogle Scholar
  16. 16.
    Rubens RD, Knight RK, Hayward JL (1975) Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32: 730PubMedCrossRefGoogle Scholar
  17. 17.
    Carmo-Pereira J, Costa FO, Henriques E (1980) Single drug versus combination cytotoxic chemotherapy in advanced breast cancer: a randomized study. Eur J Cancer 16: 1621PubMedGoogle Scholar
  18. 18.
    Muss HB, White DR, Cooper MR, et al (1977) Combination chemotherapy in advanced breast cancer: a randomized trial comparing a three-versus a five-drug program. Arch Intern Med 137: 1711PubMedCrossRefGoogle Scholar
  19. 19.
    Brunner KW, Sonntag RW, Martz G, et al (1975) A controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36: 1208PubMedCrossRefGoogle Scholar
  20. 20.
    Kennealey GT, Boston B, Mitchell MS, et al (1978) Combination chemotherapy for advanced breast cancer. Two regimens containing adriamycin. Cancer 42: 27CrossRefGoogle Scholar
  21. 21.
    Trannum BL, McDonald B, Thigpen T, et al (1982) Adriamycin combinations in advanced breast cancer. Cancer 49: 835CrossRefGoogle Scholar
  22. 22.
    Tormey DC (1975) Adriamycin in breast cancer: an overview of studies. Cancer Chemother Rep 6: 319Google Scholar
  23. 23.
    Hoogstraten B, George SL, Samal B, et al (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13PubMedCrossRefGoogle Scholar
  24. 24.
    French Epirubicin Study Group (1988) A prospective randomized phase Ill trial comparing combination chemotherapy with cyclophosphamide, 5-fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 4: 679Google Scholar
  25. 25.
    Italian multicenter breast study with epirubicin (1988) Phase III randomized study of 5-fluorouracil, epirubicin and cyclophosphamide versus 5-fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicenter trial. J Clin Oncol 6: 972Google Scholar
  26. 26.
    Kührer I, Ludwig H, Scheithauer W, et al (1987) Cyclophosphamid, Mitoxantron, 5-Fluorouracil und Prednisolon als Kombinationstherapie beim metastasierten Mammakarzinom. FAC 6–9: 1415Google Scholar
  27. 27.
    Manni A, Pearson OH, Brodkey J, et al (1979) Transphenoidal hypophysectomy in breast cancer. Evidence for an individual role of pituary and gonadal hormones in supporting tumor growth. Cancer 44: 2330CrossRefGoogle Scholar
  28. 28.
    Tormey DC, Gelman R, Band PR, et al (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235PubMedCrossRefGoogle Scholar
  29. 29.
    Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625PubMedCrossRefGoogle Scholar
  30. 30.
    Ahmann DL, O’Fallon J, O’Connell MJ, et al (1978) Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clin Trials 5: 219Google Scholar
  31. 31.
    Brambilla C, DeLena M, Rossi A, et al (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1: 801PubMedCrossRefGoogle Scholar
  32. 32.
    Eagan RT, Ahmann DL, Edmonson JH, et al (1975) Controlled evaluation of the combination of adriamycin (NSC-123127), vincristine (NSC-67574), and methotrexate (NSC-740) in patients with disseminated breast cancer. Cancer Chemother Rep 6: 339Google Scholar
  33. 33.
    Irwin LE, Chlebowski RT, Weiner JM, et al (1980) Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial. Cancer Treat Rep 64: 981PubMedGoogle Scholar
  34. 34.
    Nemoto T, Horton J, Simon R, et al (1982) Comparison of four combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU, and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 49: 1988PubMedCrossRefGoogle Scholar
  35. 35.
    Rainey JM, Jones SE, Salmon SE (1979) Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide. Cancer 43: 66PubMedCrossRefGoogle Scholar
  36. 36.
    Tranum B, Hoogstraten B, Kennedy A, et al (1978) Adriamycin in combination for metastatic breast cancer. Cancer 41: 2078PubMedCrossRefGoogle Scholar
  37. 37.
    Aisner J, Weinberg V, Perloff M, et al (1987) Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5: 1523PubMedGoogle Scholar
  38. 38.
    Bull JM, Tormey DC, Li SH, et al (1978) A randomized trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649PubMedCrossRefGoogle Scholar
  39. 39.
    Muss HB, White DR, Richards F, et al (1978) Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141PubMedCrossRefGoogle Scholar
  40. 40.
    Smalley RV, Lefante J, Bartolucci A, et al (1983) A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 3: 209CrossRefGoogle Scholar
  41. 41.
    Cunnings FJ, Gelmans R, Horton J (1985) Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 3: 932Google Scholar
  42. 42.
    Tormey DC, Weinberg VE, Leone LA, et al,(1984) A comparison of intermittent vs continuous and adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7: 231CrossRefGoogle Scholar
  43. 43.
    Smalley RV, Carpenter J, Bartolucci A, et al (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and CTX-MTX-5FU-VCR-P (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625CrossRefGoogle Scholar
  44. 44.
    Tormey DC, Lippman ME, Edwards BK, et al (1978) Evaluation of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy regimens for breast cancer. Proc AACR-ASCO 19: abstract #54Google Scholar
  45. 45.
    Hryniuk W, Bush H (1987) The importance of dose intensity in chemotherapy of metastatic breast cancer. Semin Oncol 4: 3Google Scholar
  46. 46.
    Bonadonna G, Valagussa P (1987) Dose response effect of CMF in breast cancer. Semin Oncol 1: 34Google Scholar
  47. 47.
    Hortobagyi G, Bodey G, Rodriguez V, et al (1987) Evaluation of high dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 3: 354Google Scholar
  48. 48.
    Jones R, Holland J, Strashun A, et al (1987) A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 2: 172Google Scholar
  49. 49.
    Williams SF, Mick R, Desser R, et al (1989) High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824PubMedGoogle Scholar
  50. 50.
    Wallerstein R, Spitzer G, Dunphy F, et al (1990) A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8: 1782PubMedGoogle Scholar
  51. 51.
    Smalley RV, Murphy S, Huguley CM Jr, et al (1976) Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 36: 3911PubMedGoogle Scholar
  52. 52.
    Coates A, Gebski V, Bishop JF, et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490PubMedCrossRefGoogle Scholar
  53. 53.
    Plotkin D, Waugh WJ (1983) Discontinuous chemotherapy for advanced breast cancer. Am J Clin Oncol 6: 375PubMedCrossRefGoogle Scholar
  54. 54.
    Hall TC, Dederick MM, Nevinney HB, et al (1963) Prognostic value of response of patients with breast cancer to therapeutic castration. Cancer Chemother Rep 31: 47PubMedGoogle Scholar
  55. 55.
    Lewison EF (1965) Castration in the treatment of advanced breast cancer. Cancer 18: 1558PubMedCrossRefGoogle Scholar
  56. 56.
    Stoll BA (1972) Castration and estrogen therapy. In: Stoll BA (ed) Endocrine therapy in malignant disease. Saunders, Philadelphia London Toronto Montreal Sydney Tokyo, p 117Google Scholar
  57. 57.
    Manni A, Santen R, Harvey H, et al (1986) Treatment of breast cancer with gonadotropin-releasing hormone. Endocrinol Rev 7: 89CrossRefGoogle Scholar
  58. 58.
    Moore FD, Van Devanter SB, Boyden CM, et al (1974) Adrenalectomy with chemotherapy in the treatment of advanced breast cancer. Objective and subjective response rates: duration and quality of life. Surgery 76: 376PubMedGoogle Scholar
  59. 59.
    Silverstein MJ, Byron RL, Yonemoto RH, et al (1975) Bilateral adrenalectomy for advanced breast cancer: a 21 year experience. Surgery 77: 825PubMedGoogle Scholar
  60. 60.
    Schmidt M, Nemoto T, Dao T, et al (1971) Prognostic factors affecting adrenalectomy in patients with metastatic cancer of the breast. Cancer 27: 1106PubMedCrossRefGoogle Scholar
  61. 61.
    Kaufmann M, Schmid H, Kiesel L, et al (1988) GnRH-Agonisten (Zoladex)-Therapie bei prämenopausalen Frauen mit metastasierendem Mammakarzinom. Geburtshilfe Frauenheilkd 48: 528CrossRefGoogle Scholar
  62. 62.
    Williams MR, Walker KJ, Turkes A, et al (1986) The use of a LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 692Google Scholar
  63. 63.
    Kaufmann M, Jonat W, Kleeberg U, et al (1989) Goserelin, a depot gonadotropinreleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7: 1113PubMedGoogle Scholar
  64. 64.
    Preis P, Langer M, Kubista E, et al (1988) Decapeptyl als therapeutische Alternative beim metastasierenden Mammakarzinom prämenopausaler Patientinnen. Acta Med Austriaca 15: 78Google Scholar
  65. 65.
    Harper MJK, Walpole AL (1967) A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13: 101PubMedCrossRefGoogle Scholar
  66. 66.
    Jordan VC (1976) Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 60: 1409PubMedGoogle Scholar
  67. 67.
    Jordan VC (1988) Chemosuppression of breast cancer with tamoxifen — laboratory evidence and future clinical investigation. Cancer Invest 6: 589PubMedCrossRefGoogle Scholar
  68. 68.
    Jordan VC (1986) Estrogen/antiestrogen action and breast cancer therapy. Madison, University of WisconsinGoogle Scholar
  69. 69.
    Jordan VC (1984) Biochemical pharmacology of antiestrogenic action. Pharmacol Rev 36: 245PubMedGoogle Scholar
  70. 70.
    Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127PubMedCrossRefGoogle Scholar
  71. 71.
    Osborne CK, Boldt DH, Clark GM, et al (1983) Effects of tamoxifen in human breast cancer cell kinetics: accumulation of cells in early GI phase. Cancer Res 43: 3583PubMedGoogle Scholar
  72. 72.
    Sutherland RN, Green MD, Hall RE, et al (1983) Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the GO/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19: 615PubMedCrossRefGoogle Scholar
  73. 73.
    Bénry J, Green BJ, Matheson DS (1987) Modulation of natural killer cell activity by tamoxifen in stage I postmenopausal breast cancer. Eur J Cancer Clin Oncol 23: 517CrossRefGoogle Scholar
  74. 74.
    Patterson JS, Battersby LA, Edwards DG (1982) Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocr Rel Cancer [Suppl 9]: 563Google Scholar
  75. 75.
    Legha S, Muggia FM (1976) Antiestrogens in the treatment of cancer. Ann Intern Med 84: 751PubMedGoogle Scholar
  76. 76.
    Mouridsen H, Palshof T, Patterson J (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rep 62: 131CrossRefGoogle Scholar
  77. 77.
    Heel RC, Brogden RN, Speight TM, et al (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1PubMedCrossRefGoogle Scholar
  78. 78.
    Pearson OH, Manni A, Arafah BM (1982) Antiestrogen treatment of breast cancer: an overview. Cancer Res 42: 3424Google Scholar
  79. 79.
    Pritchard KI, Thomson DB, Myers RE, et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787PubMedGoogle Scholar
  80. 80.
    Pritchard I, Meakin JW, Sawka C, et al (1985) The role and mechanism of action of tamoxifen in premenopausal women with metastatic carcinoma of the breast. Proc ASCO 4: 54 (abstract # C-206)Google Scholar
  81. 81.
    Hoogstraten B, Fletcher WS, Gad-el-Mawla N, et al (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. Cancer Res 42: 4788PubMedGoogle Scholar
  82. 82.
    Planting A, Wijst JM, Alexieva-Figuseh J (1983) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Proc 3rd EORTC Breast Cancer Conference 9: 17 (abstract)Google Scholar
  83. 83.
    Tormey DC, Lippman ME, Edwards BK (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139PubMedGoogle Scholar
  84. 84.
    Asbury RF, Bakemeier RF, Folsch E, et al (1981) Treatment of metastatic breast cancer with aminoglutethimide. Cancer 47: 1954PubMedCrossRefGoogle Scholar
  85. 85.
    Griffiths CT, Hall TC, Saba Z, et al (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31PubMedCrossRefGoogle Scholar
  86. 86.
    Smith IE, Fitzharris BM, McKinna JA, et al (1978) Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet 11: 646CrossRefGoogle Scholar
  87. 87.
    Wells SA Jr, Santen RJ, Lipton A, et al (1978) Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187: 475PubMedCrossRefGoogle Scholar
  88. 88.
    Kühböck J, Ludwig H, Pötzi P, et al (1985) Aminoglutethimidtherapie beim fortgeschrittenen Mammakarzinom. Wien Med Wochenschr: 608Google Scholar
  89. 89.
    Brodie AMH, Garrett WM, Hendrickson JR, et al (1983) Aromatase inhibitors, their pharmacology and application. J Steroid Biochem 19: 53PubMedCrossRefGoogle Scholar
  90. 90.
    Coombes RC, Dowsett M, Goss P, et al (1984) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet i:1237Google Scholar
  91. 91.
    Coombes RC, Goss PE, Dowsett M, et al (1987) 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Tumor Diagnostik & Therapie 8: 271Google Scholar
  92. 92.
    Dowsett M, Goss PE, Powles TJ, et al (1987) Use of the aromatase inhibitor 4hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 47: 1957PubMedGoogle Scholar
  93. 93.
    Goss PE, Powles TJ, Dowsett M, et al (1986) Treatment of advanced premenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46: 4823PubMedGoogle Scholar
  94. 94.
    Höffken K, Jonat W, Possinger K, et al (1990) Aromatase inhibition with 4hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol 8: 875PubMedGoogle Scholar
  95. 95.
    Bojar H (1983) Die Entwicklung der Rezeptorforschung, insbesondere in bezug auf die hochdosierte MAP-Therapie. In: Nagel GA, Robustelli del la Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 23Google Scholar
  96. 96.
    Lang I, Zielinski CC, Tempi H, et al (1990) Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor. Cancer 66: 1949PubMedCrossRefGoogle Scholar
  97. 97.
    Cavalli F, Goldhirsch A, Jungi F, et al (1983) Eine randomisierte Studie zum Vergleich einer niedrigdosierten gegenüber einer hochdosierten Medroxyprogesteronazetat-Therapie bei der Behandlung von postmenopausalen Patientinnen mit fortgeschrittenem Mammakarzinom. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 147Google Scholar
  98. 98.
    Bumma C (1983) Metastasierendes Mammakarzinom auf Medroxyprogesteronazetat (MAP) und Hormonrezeptoren. In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 97Google Scholar
  99. 99.
    Mattson W (1983) Die Behandlung des fortgeschrittenen Mammakarzinoms mit hochdosiertem Medroxyprogesteronazetat (HD-MAP). In: Nagel GA, Robustelli della Cuna G, Lanius P (Hrsg) Deutsch-Italienisches Onkologisches Symposium (MAP). Kehrer, Freiburg, S 139Google Scholar
  100. 100.
    Pannuti F, Martoni A, Lenaz C, et al (1978) A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62: 499PubMedGoogle Scholar
  101. 101.
    Robustelli della Cuna G, Caiciati A, Bernardo Strada MR, et al (1978) High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose response evaluation. Tumori 64: 143Google Scholar
  102. 102.
    De Lena M, Brambilla C, Valagussa P, et al (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175PubMedCrossRefGoogle Scholar
  103. 103.
    Ahmann DL, O’Connell MJ, Hahn RG, et al (1977) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 297: 356PubMedCrossRefGoogle Scholar
  104. 104.
    Cavalli F, Beer M, Martz G, et al (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research. Br Med J 2: 865Google Scholar
  105. 105.
    Falkson G, Falkson HC, Glidewell O, et al (1979) Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 43: 2215PubMedCrossRefGoogle Scholar
  106. 106.
    Lloyd RE, Jones SE, Salmon SE (1979) Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer 43: 60PubMedCrossRefGoogle Scholar
  107. 107.
    Ahmann DL, Green SJ, Bisel HF, et al (1982) An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 5: 355PubMedCrossRefGoogle Scholar
  108. 108.
    Cocconi G, DelLisi V, Boni C, et al (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer 51: 581PubMedCrossRefGoogle Scholar
  109. 109.
    Brunner KW, Sonntag RW, Alberto P, et al (1977) Combined chemo-and hormonal therapy in advanced breast cancer. Cancer 39: 2923PubMedCrossRefGoogle Scholar
  110. 110.
    Rubens RD, Begent RHJ, Knight RK, et al (1978) Combined cytotoxic and progestagen therapy for advanced breast cancer. Cancer 42: 1680PubMedCrossRefGoogle Scholar
  111. 111.
    Mouridsen HT, Palshof T, Engelsman E, et al (1980) CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Eur J Cancer 1 [Stipp!’: 119PubMedGoogle Scholar
  112. 112.
    Mouridsen HT, Rose C, Engelsman E, et al (1985) Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC Breast Cancer Cooperative Group study of CMF versus CMF plus tamoxifen. Eur J Cancer Clin Oncol 21: 291PubMedCrossRefGoogle Scholar
  113. 113.
    Lippman ME, Cassidy J, Wesley M, et al (1984) A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 2: 28PubMedGoogle Scholar
  114. 114.
    Allegra JC, Woodcock TM, Richman SP, et al (1982) A phase II trial of tamoxifen, premarin, methotrexate, and 5-fluorouracil in metastatic breast cancer. Breast Cancer Treat Rep 2: 93CrossRefGoogle Scholar
  115. 115.
    Bowman D (1983) A phase II evaluation of sequential tamoxifen, premarin, methotrexate, and 5-fluorouracil in refractory stage IV breast cancer. Proc ASCO 2: 106 (abstract)Google Scholar
  116. 116.
    Kührer I, Gisslinger H, Scheithauer W, et al (1990) Conventional versus cytokinetic polychemotherapy in patients with advanced breast cancer: a randomized phase Ill study. Blut 61: 336 (abstract # A 55)Google Scholar
  117. 117.
    Nash CH, Jones SE, Moon TE, et al (1980) Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46: 2380PubMedCrossRefGoogle Scholar
  118. 118.
    Mohla S, Sampson CC, Khan T, et al (1982) Estrogen and progesterone receptors in breast cancer in black Americans. Cancer 50: 552PubMedCrossRefGoogle Scholar
  119. 119.
    Swenerton KD, Legha SS, Smith T, et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552PubMedGoogle Scholar
  120. 120.
    Decker DA, Ahmann DL, Bisel HF, et al (1979) Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA 242: 2075PubMedCrossRefGoogle Scholar
  121. 121.
    Valagussa P, Brambilla C, Bonadonna G (1979) Advanced breast cancer. Are the traditional stratification parameters still of value when patients are treated with combination chemotherapy? Eur J Cancer 15: 565PubMedGoogle Scholar
  122. 122.
    Bull JM, Tormey DC, Li SH, et al (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649PubMedCrossRefGoogle Scholar
  123. 123.
    George SL, Hoogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60: 731PubMedGoogle Scholar
  124. 124.
    Corle DK, Sears ME, Olson KB (1984) The relationship of quantitative estrogen receptor level and clinical response to cytotoxic chemotherapy in advanced breast cancer: an extramural analysis. Cancer 54: 1554PubMedCrossRefGoogle Scholar
  125. 125.
    Mörz R, Francesconi M, Schemper M, et al (1982) The value of prognostic parameters for the stratification of advanced breast cancer patients. J Cancer Res Clin Oncol 102: 289PubMedCrossRefGoogle Scholar
  126. 126.
    Tormey DC, Falkson G, Simon RM, et al (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247Google Scholar
  127. 127.
    DeWys WD, Begg C, Band P, et al (1981) The impact of malnutrition on treatment results in breast cancer. Cancer Treat Rep 65: 87PubMedGoogle Scholar
  128. 128.
    Derogatis LR, Abeloff MD, Melisaratos N (1979) Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242: 1504PubMedCrossRefGoogle Scholar
  129. 129.
    Cassileth BR, Lusk EJ, Miller DS, et al (1985) Psychosocial correlates of survival in advanced malignant disease? N Engl J Med 312: 1551PubMedCrossRefGoogle Scholar
  130. 130.
    Coburn J, Ahmann FR, Moon T, et al (1983) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. Breast Cancer Res Treat 3: 303CrossRefGoogle Scholar
  131. 131.
    Valagussa P, Rossi A, Tancini G, et al (1985) Is there any effective salvage treatment for relapsing operable breast cancer with N+? Proc ASCO 4: 56 (abstract # C-215)Google Scholar
  132. 132.
    Bitran JD, Desser RK, Shapiro CM, et al (1983) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51: 381PubMedCrossRefGoogle Scholar
  133. 133.
    Buzdar AU, Legha SS, Hortobagyi GN, et al (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47: 2798PubMedCrossRefGoogle Scholar
  134. 134.
    Preda F, Oriana S, Perozziello F, et al (1982) Clinical response to chemotherapy and hormone therapy as first treatment after therapeutic ovariectomy in advanced breast cancer patients. Tumori 68: 1982Google Scholar
  135. 135.
    Oberfield RA, Cady B, Pazianos AG, et al (1979) Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. Surg Gynecol Obstet 148: 881PubMedGoogle Scholar
  136. 136.
    Kiang DT, Kennedy BJ (1981) Chemoendocrine therapy in advanced breast cancer. Breast Cancer Res Treat 1: 105PubMedCrossRefGoogle Scholar
  137. 137.
    Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111PubMedGoogle Scholar
  138. 138.
    Legha SS, Buzdar AU, Smith TL, et al (1980) Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438PubMedCrossRefGoogle Scholar
  139. 139.
    Chang JC, Wegowske G (1981). Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. Cancer 48: 2503PubMedCrossRefGoogle Scholar
  140. 140.
    Cocconi G, DeLisi V, Mori P, et al (1982) Estrogen receptors and response to chemotherapy in advanced breast cancer. Tumori 68: 67PubMedGoogle Scholar
  141. 141.
    Jonat W, Maas H, Stolzenbach G, et al (1980) Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 46: 2809PubMedCrossRefGoogle Scholar
  142. 142.
    Rubens RD, Hayward JL (1980) Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922PubMedCrossRefGoogle Scholar
  143. 143.
    Hilf R, Feldstein ML, Savlov ED, et al (1980) The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797PubMedCrossRefGoogle Scholar
  144. 144.
    Hilf R, Feldstein ML, Gibson SL, et al (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45: 1993PubMedCrossRefGoogle Scholar
  145. 145.
    Samal BA, Brooks SC, Cummings G, et al (1980) Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer 46: 2925PubMedCrossRefGoogle Scholar
  146. 146.
    Young PCM, Ehrlich CE, Einhorn LH (1980) Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 46: 2961PubMedCrossRefGoogle Scholar
  147. 147.
    Kiang DT, Frenning DH, Gay J, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46: 2814PubMedCrossRefGoogle Scholar
  148. 148.
    Kiang DT, Frenning DH, Goldman Al, et at (1978) Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299: 1330CrossRefGoogle Scholar
  149. 149.
    Lippman ME, Allegra JC, Thompson EB, et al (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223PubMedCrossRefGoogle Scholar
  150. 150.
    Mortimer J, Reimer R, Greenstreet R, et at (1981) Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 65: 763PubMedGoogle Scholar
  151. 151.
    Rosenbaum C, Marsland TA, Stolbach LL, et at (1980) Estrogen receptor status and response to chemotherapy in advanced breast cancer: the Tufts-Shattuck-Pondville experience. Cancer 46: 2919CrossRefGoogle Scholar
  152. 152.
    Samann NA, Buzdar AU, Aldinger KA, et at (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47: 554CrossRefGoogle Scholar
  153. 153.
    Bloom ND, Tobin EH, Schreibman B, et at (1980) The role of progesterone receptors in the management of advanced breast cancer. Cancer 45: 2992PubMedCrossRefGoogle Scholar
  154. 154.
    Osborne C, Yochmowitz M, Knight W, et at (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884CrossRefGoogle Scholar
  155. 155.
    Rozenczweig M, Staquet MJ, VonHoff DD, et at (1979) Prognostic factors for the response to chemotherapy in advanced breast cancer. Cancer Clin Trials 2: 165Google Scholar
  156. 156.
    Fey MF, Brunner KW, Sonntag RW (1981) Prognostic factors in metastatic breast cancer. Cancer Clin Trials 4: 237PubMedGoogle Scholar
  157. 157.
    Spiegel D, Kraemer HC, Bloom JR, et al (1989) Effect of psychological treatment on survival of patients with metastatic breast cancer. Lancet 1: 888CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1992

Authors and Affiliations

  • C. Zielinski

There are no affiliations available

Personalised recommendations